WALTHAM, Mass. / Apr 09, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM... Read More

WALTHAM, Mass. / Feb 27, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on... Read More

Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK ® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with... Read More

WALTHAM, Mass. / Feb 01, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera’s... Read More

WALTHAM, Mass. / Feb 01, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday,... Read More

Median Overall Survival for QINLOCK ® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer Patients with Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Lower Rate of Treatment Discontinuations Due to TEAEs with QINLOCK Versus Sunitinib WALTHAM, Mass. / Jan 18, 2024 / Business Wire / Deciphera... Read More

Preliminary Unaudited Fourth Quarter 2023 QINLOCK ® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT); Commercial Launch Preparations Underway Expects to Initiate a... Read More

Median Progression-Free Survival for QINLOCK ® of 14.2 Months Versus 1.5 Months for Sunitinib Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib Median Overall Survival for QINLOCK was Not Estimable Versus 17.5 Months for Sunitinib Results Support Ongoing Pivotal Phase 3 INSIGHT Study WALTHAM, Mass. / Jan 05, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company... Read More

WALTHAM, Mass. / Jan 02, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 4:30 PM... Read More

WALTHAM, Mass. / Nov 29, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023... Read More

WALTHAM, Mass. / Nov 07, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies London Healthcare Conference on Tuesday,... Read More

Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK ® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 Announced Positive Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib for TGCT and Updated Results from Phase 1/2 Study; NDA Submission Expected in Second Quarter of 2024 QINLOCK Successfully Launched in Italy Conference Call to be Held Today at 8:00 AM... Read More

MOTION Study Met Primary Endpoint with Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo (p<0.0001) MOTION Study Met All Key Secondary Endpoints with Statistically Significant and Clinically Meaningful Improvements at Week 25 Compared to Placebo, including ORR by Tumor Volume Score (TVS) of 67% vs. 0% (p< 0.0001) Updated Results from Phase 1/2 Study of Vimseltinib Demonstrated Best ORR of 72% (Phase... Read More

This marks a significant step forward in the multi-regional partnership between Deciphera and Medison ZUG, Switzerland and TORONTO , Sept. 29, 2023 /CNW/ -- Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the public formulary listing of QINLOCK® in Canadian provinces: Ontario and Quebec . These... Read More

WALTHAM, Mass. / Sep 15, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the hiring of Dashyant Dhanak, Ph.D., Executive Vice President and Chief Scientific Officer, the Compensation Committee of Deciphera’s Board... Read More

WALTHAM, Mass. / Aug 18, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the hiring of Kevin Brodbeck, Senior Vice President and Chief Technical Officer, the Compensation Committee of Deciphera’s Board of... Read More

Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-line GIST Patients with Mutations in KIT Exon 11 and 17/18 Initiated with First Sites Open for Enrollment DCC-3116... Read More

Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member WALTHAM, Mass. / Aug 03, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company’s Founder, Executive Vice President,... Read More

WALTHAM, Mass. / Aug 02, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2023 financial results on Wednesday, August 9, 2023. In connection with the earnings release, Deciphera’s management team... Read More

Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline Encore Oral Presentation of Results of ctDNA Analysis of INTRIGUE Phase 3 Study in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Which Demonstrated Substantial Clinical Benefit from QINLOCK but Not Sunitinib... Read More

WALTHAM, Mass. / May 23, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on... Read More

WALTHAM, Mass. / May 08, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New... Read More

First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 Enrollment Complete in the MOTION Pivotal Phase 3 Study of Vimseltinib; Top-line Results Expected in the Fourth Quarter of 2023 QINLOCK Granted FDA Breakthrough Therapy Designation in Second-line GIST Patients with Mutations in KIT Exon 11 and 17/18 and Included in NCCN Guidelines... Read More

WALTHAM, Mass. / Apr 26, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera’s management team will... Read More

WALTHAM, Mass. / Apr 19, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET. A... Read More

WALTHAM, Mass. / Mar 14, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that QINLOCK® (ripretinib) has been included in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology as a preferred... Read More

WALTHAM, Mass. / Mar 14, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023. The Company will also host a... Read More

WALTHAM, Mass. / Feb 27, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday,... Read More

WALTHAM, Mass. / Feb 02, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Guggenheim Healthcare Talks Oncology Day on Thursday,... Read More

WALTHAM, Mass. / Jan 31, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023. In connection with the earnings release, Deciphera’s... Read More

Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK ® but Not Sunitinib Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical Study in the Second Half of 2023 WALTHAM, Mass. / Jan 25, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing... Read More

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share. The aggregate gross proceeds to Deciphera from this offering are expected to... Read More

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to an... Read More

Plans to Initiate Pivotal Phase 3 INSIGHT Study of QINLOCK ® Versus Sunitinib in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only in the Second Half of 2023 Based on ctDNA Analysis from INTRIGUE Study Expects to Complete Enrollment in the Pivotal Phase 3 MOTION Study of Vimseltinib in the First Half of 2023 and Announce Top-line Results in the Fourth Quarter of 2023 Expects to Evaluate DCC-3116 in a... Read More

Median Progression Free Survival for QINLOCK of 14.2 Months Versus Sunitinib of 1.5 Months; Hazard Ratio of 0.22, nominal p value <0.0001 Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib; nominal p value 0.0001 Median Overall Survival for QINLOCK was Not Estimable Versus 17.5 Months for Sunitinib; Hazard Ratio of 0.34, nominal p value 0.0061 Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical... Read More

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations . A... Read More